Novo Nordisk, Eli Lilly Cut GLP-1 Prices for Expanded Medicare Market Access
Novo Nordisk and Eli Lilly agree to lower GLP-1 drug prices in exchange for expanded Medicare and Medicaid coverage, marking a major shift in U.S. drug pricing and access.
Trump Administration Secures Drug Price Reductions for Weight-Loss Meds in Medicare
The Trump administration announces agreements with Eli Lilly and Novo Nordisk to lower prices and expand Medicare coverage for weight-loss drugs like Wegovy and Zepbound, effective 2026.
Pharma’s New Patient Access Website: A Signal for Insurers?
PhRMA introduces an online platform connecting patients with discounted pharmaceuticals as the U.S. government pressures drug companies to reform pricing and distribution.
Impact of MFN Drug Pricing Policy on Medicare Part D Deadline Approaches
The looming deadline for drugmakers to comply with the Most Favored Nation drug pricing policy raises concerns over potential disruptions to Medicare Part D, highlighting regulatory and market risks for U.S. drug pricing and federal entitlement programs.
Medicare Changes to Orphan Drug Price Negotiation Increase Costs
Recent legislative changes to Medicare’s drug price negotiation program expand orphan drug exclusions, delaying price negotiation for expensive specialty drugs and increasing costs for Medicare beneficiaries.
GLP-1 Drugs Pose Coverage Challenges Amid Proven Health Benefits
Analysis finds GLP-1 drugs like semaglutide offer real health benefits but raise insurance coverage and cost challenges amid growing demand in the U.S. market.
Top 5 U.S. Health Policy Priorities for Congress Post-Recess
Congress returns from recess with five key U.S. health policy priorities including FY26 appropriations, OTC drug fee program reauthorization, drug pricing reform, Medicare/Medicaid extenders, and ACA tax credits.
Medicare Coverage Limits for Saxenda Highlight Challenges in Weight Loss Drug Access
Explore Medicare coverage limitations for Saxenda, a GLP-1 agonist approved for weight loss, and the implications for obesity drug access and insurance plan strategies.
Medicare Part D Premiums May Rise Up to $50 Monthly in 2025
Medicare Part D enrollees may face significant premium hikes up to $50 monthly in 2025 due to increased drug spending, policy changes, and reduced federal stabilization funding. Compare plans during open enrollment.
CMS Proposes Voluntary Medicaid and Medicare GLP-1 Coverage Trial
CMS plans a voluntary five-year trial allowing state Medicaid and Medicare Part D plans to cover GLP-1 weight management drugs, including Ozempic and Wegovy, starting in 2026-27 amid pricing and coverage challenges.